A composition for therapeutic use, the composition comprising a 2-(acylamino)imidazole compound selected from the group consisting of and salts thereof wherein: R 1 is halophenyl; X is a member selected from the group consisting of a bond, O, and NR 5a; Y is a member selected from the group consisting of O, S, or NR 5b; wherein when X is O or a bond, Y is O; R 2 is a member independently selected from the group consisting of hydrogen, alkyl, fluoroalkyl, alkenyl, arylalkyl, acyl, and carbamoyl; R 3 is alkyl; R 4a and R 4b are each a member independently selected from the group consisting of hydrogen, alkyl, fluoro, fluoroalkyl, alkenyl, aryl, and heteroaryl; or, alternatively, the two R 4 join to form a spirocycloalkyl ring; R 5a and R 5b are each a member independently selected from the group consisting of hydrogen, alkyl, fluoroalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, arylalkyl, and heteroarylalkyl; each A n of the A n members is independently selected from the group consisting of N and CR 6n; each of the R 6n members is independently selected from the group consisting of hydrogen, alkyl, hydroxy, alkoxy, aminoalkoxy, alkylamino, alkylaminoalkoxy, alkenyl, alkynyl aryl, aryloxy, arylamino, cycloalkyl, cycloalkylalkyl, cycloalkoxy, cycloalkylalkoxy, cycloalkylamino, cycloalkylalkylamino, heterocyclyl, heterocycyloxy, heterocycylamino, halo, haloalkyl, fluoroalkyloxy, heteroaryl, heteroaryloxy, heteroarylamino, arylalkyl, arylalkyloxy, arylalkylamino, heteroarylalkyl, heteroarylalkyloxy, and heteroarylalkylamino; or, alternatively, a pair of adjacent R 6n members join to form an additional fused ring that is selected from the group consisting of cycloalkyl, aryl, heterocyclyl, and heterocycloaryl; and R 7 is a member independently selected from the group consisting of alkyl, aminoalkyl, alkenyl, arylalkyl, and heteroarylalkyl. R 1 is halophenyl; X is a member selected from the group consisting of a bond, O, and NR 5a; Y is a member selected from the group consisting of O, S, or NR 5b; wherein when X is O or a bond, Y is O; R 2 is a member independently selected from the group consisting of hydrogen, alkyl, fluoroalkyl, alkenyl, arylalkyl, acyl, and carbamoyl; R 3 is alkyl; R 4a and R 4b are each a member independently selected from the group consisting of hydrogen, alkyl, fluoro, fluoroalkyl, alkenyl, aryl, and heteroaryl; or, alternatively, the two R 4 join to form a spirocycloalkyl ring; R 5a and R 5b are each a member independently selected from the group consisting of hydrogen, alkyl, fluoroalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, arylalkyl, and heteroarylalkyl; each A n of the A n members is independently selected from the group consisting of N and CR 6n; each of the R 6n members is independently selected from the group consisting of hydrogen, alkyl, hydroxy, alkoxy, aminoalkoxy, alkylamino, alkylaminoalkoxy, alkenyl, alkynyl aryl, aryloxy, arylamino, cycloalkyl, cycloalkylalkyl, cycloalkoxy, cycloalkylalkoxy, cycloalkylamino, cycloalkylalkylamino, heterocyclyl, heterocycyloxy, heterocycylamino, halo, haloalkyl, fluoroalkyloxy, heteroaryl, heteroaryloxy, heteroarylamino, arylalkyl, arylalkyloxy, arylalkylamino, heteroarylalkyl, heteroarylalkyloxy, and heteroarylalkylamino; or, alternatively, a pair of adjacent R 6n members join to form an additional fused ring that is selected from the group consisting of cycloalkyl, aryl, heterocyclyl, and heterocycloaryl; and R 7 is a member independently selected from the group consisting of alkyl, aminoalkyl, alkenyl, arylalkyl, and heteroarylalkyl.